Figure 3.

AAV G-CSF improves motor functions of SOD-1 (G93A) mice. (a) Muscular strength measured by the grip strength test. AAV G-CSF treatment leads to a relative preservation of the muscular strength of SOD-1 (G93A) mice at the mid- to end-point of the disease (n = 12). (b) Performance on Rotarod. AAV G-CSF treatment leads to an improvement of endurance/coordination performance at the mid- to end-point of the disease (n = 12). AAV, adeno-associated virus; eGFP, enhanced green fluorescent protein; G-CSF, granulocyte-colony stimulating factor.